1 Full title

2	Prednisone enhances pregnancy outcomes in gonadotropin-releasing
3	hormone antagonist protocol: a multi-center randomized clinical trial
4	
5	Short title
6	Prednisone in gonadotropin-releasing hormone antagonist protocol
7	
8	Dan Zhang ¹¹ , Xian Wu ¹¹ , Ai-Fang Jiang ²¹ , Tingting Yang ²¹ , Shu-Qin Zhao ³¹ , Lei Wang ³ , Jian Li ⁴ , Yan
9	Li ¹ , Xiao-Wei Zhou ¹ , Lan Xia ¹ , Shen Zhao ¹ , Hui-Hui Xu ¹ , Xiao-Ling Wang ¹ , Yao Qu ² , Hsun-Ming
10	Chang ⁵ , Ai-Jun Zhang ^{1,6&} , Chun-E Ren ^{2&} , Bu-Fang Xu ^{1,7&*}
11	
12	1. Reproductive Medical Center, Department of Obstetrics and Gynecology, Ruijin Hospital,
13	Shanghai Jiao Tong University School of Medicine, Shanghai, China
14	2. Department of Reproductive Medicine, Affiliated Hospital of Shandong Second Medical
15	University, Weifang, Shandong, China
16	3. Maternal and Child Health Care Hospital of Zaozhuang, Shandong, China
17	4. Clinical research center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,
18	Shanghai, China
19	5. Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung,
20	Taiwan
21	6. Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai,
22 N	China OTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 7. Shanghai Key Laboratory of Reproductive Medicine, Department of Histoembryology, Genetics
- 24 and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- ^{*} Corresponding author:
- 27 E-mail: <u>bufangxu@163.com.cn</u> (B-F X)
- 29 ¹ These authors contributed equally to this work.
- 30 [&] These authors also contributed equally to this work.

44 **Abstract:**

45 Background

The gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol in controlled 46 47 ovarian stimulation (COS) has distinct advantages and become widespread. However, 48 the dose-dependent disturbance of GnRH-ant on endometrial immune factors may negatively impact endometrial receptivity, potentially contributing to lower clinical 49 pregnancy rates in fresh embryo transfer cycles, thereby diminishing the benefits of 50 51 this protocol. Identifying strategies to mitigate these adverse effects on the 52 endometrium is crucial for improving pregnancy outcomes in fresh embryo transfer cycles following this COS protocol. Prednisone, a primary immunosuppressive agent, 53 has been proposed as a means to counteract the negative effects of GnRH-ant on the 54 55 endometrium. This study designed a multi-center randomized clinical trial to compare the efficacy of combining prednisone with a fixed full-dose GnRH-ant 56 57 protocol versus a flexible half-dose GnRH-ant protocol and a conventional fixed 58 full-dose GnRH-ant protocol.

59 Methods and Findings

We conducted a randomized, controlled, open-label clinical trial across three reproductive centers in China from April 2019 to November 2022, with follow-up completed in August 2023. Of the 5,042 identified patients aged 20 to 35 years undergoing in vitro fertilization and embryo transfer (IVF-ET) with the GnRH-ant

64	protocol, 2,052 patients without contraindications for fresh embryo transfer were
65	enrolled. Participants were randomly assigned to three groups: Group A received a
66	fixed full-dose GnRH-ant combined with prednisone 10 mg per day from the start day
67	of stimulation until 11 to 14 days after embryo transfer; Group B received a flexible
68	half-dose GnRH-ant; and Group C received a fixed full-dose GnRH-ant. The primary
69	outcome, clinical pregnancy rate (CPR), was defined as the ultrasound confirmation
70	of an intrauterine gestation sac 30 to 35 days after embryo transfer, divided by the
71	number of cases that underwent transfer. Of the enrolled patients, 1,512 (73.7%)
72	underwent embryo transfer. Group A demonstrated a significantly higher CPR (63.1%)
73	compared to Group B (54.7%; rate difference (RD) 8.4%, 95% confidence interval (CI)
74	2.4%–14.5%, P = 0.007) and Group C (46.4%; RD 16.7%, 95% CI 10.7%–22.7%, P <
75	0.001). The cancellation rate of fresh embryo transfer in Group A (18.7%) was similar
76	to that in Group C (19.9%), but significantly lower than in Group B (24.1%). No
77	significant differences in embryo laboratory results or in adverse events were
78	observed among the groups.

79 **Conclusions**

In patients undergoing IVF with the GnRH-ant protocol, the addition of low dose prednisone significantly improved the CPR without increasing adverse effects. These findings suggest an optimal strategy to enhance the success of the antagonist protocol in IVF-ET.

84 **Trial registration** Chinese clinical trial registry: ChiCTR1900021024.

85

Key words: gonadotrophin-releasing hormone antagonist, prednisone, clinical
 pregnancy rate, fresh embryo transfer, in vitro fertilization

88 Introduction

Infertility affects a significant number of couples worldwide, and in vitro fertilization 89 and embryo transfer (IVF-ET) stands as the foremost medical solution for addressing 90 91 infertility [1]. Among the various controlled ovulation stimulation (COS) protocols, 92 the gonadotrophin-releasing hormone antagonist (GnRH-ant) offers notable 93 advantages, including a flexible, safe, and short stimulation period [2-5]. The guidelines for COS formulated by the European Society of Human Reproduction and 94 95 Embryology in 2020 recommend the GnRH-ant protocol as the first-line choice for 96 patients with various ovarian responses[6]. Especially during the COVID-19 pandemic, the characteristics of the GnRH-ant protocol effectively met the need to reduce the 97 risk of infection for patients and staff, leading to its widespread acceptance and 98 99 adoption[7]. Survey data indicate an increasing use of GnRH-ant protocol in China, 100 from 6% in 2014 to 37% in 2021[8]. Additionally, an annual report from Germany in 101 2021 showed that the proportion of GnRH-ant protocol adopted in COS reached 102 70%[9].

However, previous studies have reported lower clinical pregnancy rate (CPR) and live birth rate (LBR) of fresh embryo transfer following GnRH-ant protocol than GnRH agonist long protocol in general IVF patients [2, 10-13]. While no significant difference about pregnancy rates had been observed among frozen-thawed embryo

transfer (FET) cycles between the two protocols [14], which indicated that GnRH-ant 107 108 did not compromise the quality of embryos but may affect endometrial receptivity. 109 Although a large sample size randomized controlled trial (RCT) study of Zijiang Chen's 110 team showed no difference in pregnancy rates between fresh and frozen embryo 111 transfers among normal ovulating patients who were undergoing IVF with GnRH-ant protocol [15], another RCT from the same team showed that frozen single blastocyst 112 113 transfer resulted in a higher LBR than fresh single blastocyst transfer when using 114 GnRH-ant protocol [16], which suggested the decreased endometrial receptivity 115 during a fresh embryo transfer cycle was the main concern, and the cleavage staged 116 and multiple embryos transfer of the former study may interfere the results. To eliminate the side effect of GnRH-ant and improve clinical pregnancy rates, various 117 118 strategies have been employed, such as utilizing freeze-all embryo strategy followed by FET. However, FET has its limitations, including increased risk of pregnancy 119 complications and added economic and time burden for patients [16, 17]. Therefore, 120 121 finding strategies to enhance CPR and LBR in fresh embryo transfer cycles under the 122 GnRH-ant protocol, remains of great importance.

Our previous work has suggested that abnormal immunity plays a key role in the adverse effects of GnRH-ant on endometrial receptivity. Specifically, we observed heightened uterine natural killer (uNK) cells and increased expression of tumor necrosis factor-alpha (TNF $_{\alpha}$) in the endometrium during the implantation phase of women undergoing GnRH-ant protocol, with a dose-dependent relationship [18, 19]. Prednisone, a primary immunosuppressive agent, has been shown to reduce

inflammatory responses, decrease the number of uNK cells in the preimplantation endometrium, and suppress cytotoxicity and cytokine secretion [20]. Related studies have also confirmed the safety of low-dose prednisone during pregnancy for the offspring [21, 22]. Based on these findings, we hypothesize that prednisone administration could enhance endometrial receptivity in women undergoing the GnRH-ant protocol and ultimately improving pregnancy outcomes.

Theoretically, reducing the dose of antagonists could diminish its negative impact on endometrial receptivity. Also in our previous retrospective study, we demonstrated the safety and effectiveness of flexibly reducing the dosage of GnRH antagonist for patients with normal ovarian reserve [23]. Thus, in this study, we aim to assess the effects of low-dose prednisone on improving pregnancy rates in fresh ET cycles under the GnRH-ant protocol, in comparison with a flexible half-dose GnRH-ant protocol and the conventional full-dose GnRH-ant protocol.

142 Methods

143 Study design

This multicenter, open-label, randomized controlled clinical trial was conducted across three sites in China (Reproductive Medical Center of Ruijin Hospital, Shanghai; Department of Reproductive Medicine, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong; and Maternal and Child Health Care Hospital of Zaozhuang, Shandong) from April 2019 to November 2022, with follow-up completed in August 2023 (We originally planned to complete patients recruitment in 2 years and follow up for another 1 year, and total 3 years to complete the study.

However, due to the COVID-19 pandemic during 2020 to 2022, our recruitment 151 152 period was extended by 2 years). The study adhered to the principles outlined in the 153 Declaration of Helsinki and received approval from the institutional review board and ethics committee of Ruijin Hospital (No. 2018-185). Written informed consent was 154 obtained from all participants. The trial protocol can be found in Supplement 1 and 155 has been registered in the Chinese Clinical Trial Registry before trial commencement 156 157 (Name of the registry: The effect of flexibly reducing the dose of GnRH antagonist and adding low dose prednisone on clinical pregnancy rate in IVF antagonist cycles; 158 159 trial number: ChiCTR1900021024; trial URL: https://www.chictr.org.cn/showproj.html?proj=32931). There were no 160

the changes made to the original protocol received approval from our institutional
review board and are detailed in the end of Supplement 1.

modifications to the inclusion criteria or outcomes following the start of the trial. All

164 **Patients**

161

165 Enrollment criteria included women aged 20–35 years undergoing GnRH-ant protocol 166 and preparing for their initial IVF procedure with fresh ET. Exclusion criteria were factors that could impair pregnancy rates, such as reduced ovarian reserve [basic 167 follicle-stimulating hormone (FSH) ≥15 IU/L, bilateral antral follicle count (AFC) <5, 168 169 anti-Müllerian hormone (AMH) ≤1.1 ng/mL]; polycystic ovary syndrome patients with uncontrolled androgen levels; hydrosalpinx, endometrial polyps, moderate-to-severe 170 171 intrauterine adhesions; the presence of endometriosis, adenomyosis, or hysteromyoma (excluding subserous myoma); thyroid dysfunction, immune 172

abnormality, or insulin resistance; contraindications related to medication (e.g., allergy to the medicines involved or known contraindications for glucocorticoids); and a history of experiencing ≥ 2 spontaneous abortions.

176 Randomization and concealment of allocation

Eligible patients were randomly assigned in a 1:1:1 ratio to Groups A (adding 177 178 prednisone to conventional full-dose GnRH-ant protocol), B (receiving flexible 179 half-dose GnRH-ant), and C (receiving conventional full-dose GnRH-ant). The randomization process was conducted by an independent statistician (Dr. Jian Li), 180 181 utilizing SAS 9.2 software (SAS Institute Inc., Cary, NC, USA), employing a stratified 182 block randomization method with a block size 6 to generate corresponding random 183 numbers. These random numbers, along with the respective treatment groups, were 184 sealed within opaque envelopes, sequentially numbered, and remained unopened 185 until the participant's eligibility for the study was explicitly confirmed. The Clinician opened the envelope and assigned the participant to the corresponding intervention. 186 187 Due to the distinct drugs administered, blinding of doctors to treatment assignments 188 was impractical. Thus, masking (blinding) was not implemented in this trial.

189 **Procedures**

Recombinant FSH (rFSH; Gonal-f[®], Merck Serono) and GnRH-ant (Cetrotide[®], Merck Serono) were utilized for COS. The starting rFSH dose ranged from 100 to 400 IU, tailored to personal weight and ovarian reserve, and began on day 2 of the menstrual cycle. The daily dose was adjusted every 2 to 4 days based on individual responses by the attending physician.

Group A: Received prednisone 10 mg once daily in the morning from the start of rFSH 195 196 until 11 days after embryo transfer (ET). The prednisone was then discontinued 197 regardless of pregnancy. Patients also received a fixed dose of GnRH-ant (0.25 mg/day) from day 6 until the day of oocyte maturation triggering. Group B: Received 198 199 half-dose GnRH-ant (0.125 mg/day) from day 6 until the day of oocyte maturation triggering. During COS, the dose was increased to 0.25 mg daily when serum LH was 200 201 ≥10 mIU/mL[24] or when LH was >2×baseline (>3 mIU/mL) until the trigger day[25]. Group C: Received a fixed dose of GnRH-ant (0.25 mg/day) from day 6 until the day 202 203 of oocyte maturation triggering.

Throughout the COS process, the size of follicles, and serum LH, estradiol (E₂), and 204 progesterone levels were monitored. Human chorionic gonadotropin (HCG; Lizhu, 205 206 China) 4,000–6,000 U was administered for triggering when at least two leading 207 follicles reached an 18-mm diameter or three leading follicles reached a 17-mm diameter. Oocytes were retrieved 36 hours after triggering, and insemination was 208 209 performed on the same day. Intracytoplasmic sperm injection (ICSI) was employed in 210 cases of male factor infertility. Normal fertilization was confirmed by the presence of 211 two pronuclei 16–18 hours after insemination. Subsequently, all fertilized oocytes 212 were cultured at 37°C under 5% O_2 and 6% CO_2 in sequential media (Vitrolife, 213 Sweden). Specifically, G-1[™] plus (Vitrolife) was used for embryo culture from the pronucleate stage to day 3, followed by G-2[™] plus (Vitrolife) from day 3 to the 214 215 blastocyst stage. Embryos were evaluated on day 3 (S1 Table) or day 5 (S2 Table) after fertilization using a standardized scoring system based on morphological 216

217 characteristics[26-28].

218	Luteal support began on day 1 after oocyte retrieval, comprising 90 mg progesterone
219	sustained-release gel (Merck Sereno, France) combined with 150 mg oral
220	progesterone. For patients eligible for fresh ET, one to two available cleavage-stage
221	embryos on day 3 or blastocysts on day 5 post-oocyte retrieval were transferred
222	under ultrasound guidance. Embryo selection was based on patient preference and
223	physician judgment.

Criteria for fresh ET included: (1) $E_2 \le 7,000 \text{ pg/mL}$ on the trigger day and $\le 20 \text{ oocytes}$ retrieved; (2) oocyte stimulation duration within 8–14 days; (3) endometrial thickness 8–14 mm on the trigger day, with A or B type morphology by ultrasound; (4) progesterone $\le 1.5 \text{ ng/mL}$, or >1.5 ng/mL but <1.7 ng/mL only once throughout the COS process; (5) available embryos: cleavage stage embryo score ≥ 5 , or available day 5 blastocysts (S1 and S2 Tables).

230 Outcomes

231 The primary outcome was the CPR, defined as the number of patients achieving 232 clinical pregnancy (detection of an intrauterine gestation sac 30–35 days after fresh 233 ET) divided by the total number of cases undergoing fresh ET. Secondary outcomes 234 encompassed LBR, biochemical pregnancy rate, implantation rate, early miscarriage 235 rate, late miscarriage rate, and premature birth rate. Additionally, key embryological outcomes included mean number of retrieved oocytes, fertilization rate, available 236 237 and high-quality embryos, and cycle cancellation rate due to premature ovulation. 238 Definitions of secondary outcomes and adverse events are detailed in S3 and S4

Tables. There were no changes to the trial outcomes after the trial commenced.

240 Sample size calculation

241 Referenced to the CPRs of different protocols in recent three years in our center, the CPRs for Group A, Group B and Group C were estimated at 60%, 51% and 45%, 242 respectively. Using a bilateral α of 0.05 and power of 0.8, for the comparison 243 between Group A and Group B, the minimum sample size by Chi-square test was 244 245 determined to be 478 patients for each group. For the comparison between Group A and Group C, the calculated sample size was 173 cases for each group. However, to 246 247 ensure robust analysis, a larger sample size of 478 cases per group was used. We originally predicted a 10% cancellation rate of fresh ET and a 10% loss of follow-up, 248 and the calculated sample size was 600 for each group. But the interim analysis, 249 250 when 450 participants were enrolled in May 2021, found that the cancellation rate of 251 fresh ET in Group B was significantly higher than 10%. As a result, we revised the cancellation rate for fresh ET to 20% and increased the sample size to 684 cases per 252 group, with a total of 2,052 cases required for all three groups. 253

254 **Statistical analysis**

All statistical analyses were performed using SPSS 25.0. Analysis included both the intention-to-treat (ITT) set, which encompassed all randomized patients, and the per-protocol (PP) set, which included all patients who completed the fresh ET procedure along with follow-up visits. Our primary outcome, CPR, and pregnancy related secondary outcomes were analyzed in the PP set. The baseline characteristics and COS related secondary outcomes were analyzed in the ITT set. Continuous data

were presented as mean \pm standard deviation (SD) for normally distributed variables, 261 with between-group differences assessed through one-way analysis of variance or 262 263 Student's t-test. Non-normally distributed data were expressed as median and interguartile range (IQR) and analyzed using the non-parametric Kruskal-Walli's test. 264 For many patients in the ITT set who did not receive embryo transfer, CPR and other 265 outcomes pertaining to pregnancy were analyzed based on the PP dataset. 266 Categorical variables were presented as frequency and percentage, and inter-group 267 differences were evaluated using bilateral Pearson chi-squared or Fisher's exact 268 269 probability tests. A two-sided P < 0.05 was considered indicative of statistical 270 significance.

Rate differences (RD) and rate ratio (RR) are reported with 95% confidence intervals for both the primary outcome and second outcomes. No adjustments for multiple testing were applied to the outcomes, rendering them exploratory. A *post-hoc* subgroup analysis of the primary outcome was undertaken to explore the consistency of treatment outcomes within significant subgroups.

276 **Results**

277 **Study participants**

From April 2019 to November 2022, a total of 5,042 patients were screened for
inclusion. Of these, 2,052 were randomized for the IVF/ICSI procedure (684 per group)
and composed the ITT population. Among these, 1,512 patients underwent fresh ET
(Group A: 523; Group B: 483; and Group C: 506), constituting the PP population (Fig
1). The last patient follow-up was completed in August 2023. Baseline characteristics,

- 283 including age, BMI, infertility duration, cause of infertility, AMH, total AFC, baseline
- 284 FSH (bFSH), LH, E₂, and progesterone levels, were well balanced across the three
- groups (Table 1).

Fig 1. Flow chart of participant selection.



- Abbreviations: FSH, follicle stimulating hormone; AFC, antral follicle count; AMH, anti-Mullerian hormone; T,
- 290 testosterone; E₂, estrogen; GN, gonadotropin; HCG, human chorionic gonadotropin.
- ^a Multiple reasons for some patients.
- 292

Baseline characteristics of ITT and PP patients. Table 1 293

		ITT patients			PP patients	
	Group A	Group B	Group C	Group A	Group B	Group C
	(n=684)	(n=684)	(n=684)	(n=523)	(n=483)	(n=506)
Age, y [#]	30.4 (3.1)	30.5 (3.2)	30.7 (2.8)	30.5 (3.1)	30.6 (3.2)	30.9 (2.8)
BMI#	23.4 (3.4)	23.3 (3.6)	23.4 (3.2)	23.4 (3.4)	23.1 (3.5)	23.2 (3.1)
Infertility duration, y [#]	3.1 (2.0)	3.2 (2.2)	3.2 (2.0)	3.0 (2.1)	3.2 (2.2)	3.2 (2.1)
Type of infertility*						
Primary	318 (46.5)	353 (51.6)	352 (51.5)	244 (46.7)	245 (50.7)	260 (51.4)
Secondary	366 (53.5)	331 (48.4)	332 (48.5)	279 (53.3)	238 (49.3)	246 (48.6)
Cause of infertility*						
Male factor	61 (8.9)	64 (9.4)	62 (9.1)	43 (8.2)	45 (9.3)	43 (8.5)
Tubal	477 (69.7)	464 (67.8)	431(63.0)	375 (71.7)	343 (71.0)	337 (66.6)
Mixed factors	146 (21.3)	156 (22.8)	191 (27.9)	105 (20.1)	95 (19.7)	126 (24.9)
Antral follicle count, No.#	14.5 (7.8)	14.4 (8.0)	14.4 (8.4)	14.2 (7.7)	13.7 (7.4)	14.2 (8.1)
AMH, ng/mL [#]	4.1 (3.1)	4.5 (3.3)	4.2 (3.3)	3.7 (2.7)	3.9 (2.6)	3.6 (2.5)
Basal FSH level, mIU/mL [#]	7.1 (2.0)	7.2 (2.0)	7.3 (2.0)	7.2 (2.0)	7.4 (2.0)	7.4 (2.0)
Basal LH level, mIU/mL [#]	5.2 (3.1)	5.0 (2.7)	5.2 (3.1)	5.0 (2.9)	4.8 (2.5)	5.2 (3.0)
Basal E_2 level, pg/mL [#]	41.4 (19.9)	40.4 (30.3)	40.8 (19.6)	41.8 (21.0)	41.0 (33.9)	40.9 (19.0)
Basal progesterone, ng/mL [#]	0.5(0.5)	0.5 (0.4)	0.5 (0.5)	0.5 (0.4)	0.5 (0.4)	0.5 (0.4)

294 [#]mean (SD) , * No.(%);

295 Abbreviations: FSH, follicle stimulating hormone; BMI, body mass index; AMH, anti-Mullerian hormone; LH, 296 luteinizing hormone; E₂, estrogen; SD, standard deviation.

297

COS results 298

In the ITT patients, there were no significant differences in COS parameters between 299 300 Group A and Group C. However, in the PP patients, Group A had relatively lower 301 progesterone levels on the trigger day compared to Group C. Compared to Group B, Group A exhibited a significantly higher total GnRH-ant dose and a lower rate of 302 premature LH rise, markedly lower levels of E₂ and progesterone on trigger day, and 303 304 these findings were consistent in both ITT and PP patients (Table 2). According to the criteria, in Group B, 145 (21.2%) women in the ITT population increased their dosage 305 of GnRH-ant to full-dose, including 95 women with a LH rise ≥ 10 mIU/mL, and 50 306

- 307 women with a LH rise >2× baseline (>3 mIU/mL) during stimulation. The endometrial
- 308 thickness, and the number and quality of embryos were all balanced among groups

309 (Table 2).

Table 2. COS indexes of both ITT and PP patients and characters of

311 transferred embryos for PP patients.

	Group A	Group B	Group C	P (Group	P (Group
				A <i>vs</i> B)	A <i>vs</i> C)
ITT patients	n=684	n=684	n=684		
Starting docs of CN 11*	200.0(150.0-	200.0(150.0-	200.0(150.0-	0 5 1 4	0.057
Starting dose of GN, O	225.0)	225.0)	225.0)	0.514	0.057
Total dosage of GN, U [#]	2032.9(597.5)	2065.8(566.5)	2085.0(609.8)	0.295	0.110
Total days of GN, day*	9.0(8.0–10.0)	9.0(8.0–10.0)	9.0(8.0–10.0)	0.366	0.371
Total days of Cetrotide, day*	5.0(4.0–6.0)	5.0(4.0–6.0)	5.0(4.0–6.0)	0.366	0.371
LH on Cetrotide start day, mIU/mL*	2.9(1.7–5.4)	2.7(1.7–4.5)	3.1(1.8–6.0)	0.214	0.788
E on Catrotida start day ng/ml*	553.9(294.3–	522.0(305.0-	591.5(294.5–	0 252	0.408
L_2 on certoine start day, pg/mL	960.5)	886.0)	1016.0)	0.333	
Progesterone on Cetrotide start day, ng/mL*	0.4(0.3–0.7)	0.4(0.3–0.7)	0.5(0.3–0.8)	0.371	0.131
Total dosage of Cetrotide, mg*	1.3(1.0–1.5) ^b	0.8(0.5–0.9)ª	1.3(1.0–1.5) ^b	<0.001	0.390
LH on trigger day, mIU/mL*	2.5(1.4–4.3)	2.7(1.5–4.6)	2.6(1.5–4.0)	0.293	0.901
E on triggor day, ng/ml*	2751.6(1762.	3163.0(2041.	2786.5(1758.	<0.001	0.245
	0–4266.8)	0–4669.2)	5–4430.5)	<0.001	
Progesterone on trigger day, ng/mL [#]	1.0(0.6)	1.1(0.6)	1.0(0.6)	<0.001	0.026
Endometrial thickness on trigger day, mm [#]	11.0(1.9)	11.0(1.8)	11.0(1.8)	0.697	0.629
Premature LH rise ^{& c}	82 (12.0) ^b	146 (21.3)ª	71 (10.4) ^b	<0.001	0.345
Cycles for adjusting the Cetrotide dosage ^{& d}	NA	145(21.2)	NA	NA	NA
Cycle cancellation due to premature	0	0	0	ΝΑ	NA
ovulation(%)	0	0	0	NA	NA
Number of oocytes retrieved [#]	11.5(5.4)	11.9(5.9)	11.3(5.9)	0.198	0.557
IVE fortilization rate ⁸	5195/6490	5132/6358	5135/6379	0 220	0 510
	(80.0)	(80.7)	(80.5)	0.556	0.519
ICSI fortilization rate [®]	1046/1245	1296/1558	1007/1197	0 5 5 5	0.040
	(84.0)	(83.2)	(84.1)	0.555	0.940
Pate of available ombrues at cleavage	3613/6033	3716/6229	3636/5949	0.704	0 169
Rate of available emplyos at cleavage	(59.9)	(59.7)	(61.1)	0.794	0.108
Ton quality ombryo rate at cloavage ⁸	707/6033	790/6229	746/5949	0 102	0 160
	(11.7)	(12.7)	(12.5)	0.105	0.109
PP patients	n = 523	n = 483	n = 506		
Starting dose of GN 11*	187.5	200.0	200.0	0.216	0.065
	(150.0–225.0)	(150.0–225.0)	(150.0–225.0)	0.210	0.005

Total dosage of GN, U [#]	2027.4(573.4)	2083.2(563.9)	2087.5(607.8)	0.120	0.103
Total days of GN, day*	9.0 (8.0–10.0)	9.0 (8.0-10.0)	9.0 (9.0–10.0)	0.421	0.168
Total days of Cetrotide, day*	5.0 (4.0–6.0)	5.0 (4.0–6.0)	5.0 (5.0–6.0)	0.421	0.168
LH on Cetrotide start day, mIU/mL*	2.7 (1.7–4.6)	2.6 (1.7–4.0)	2.9 (1.7–5.2)	0.378	0.672
E on Catrotido start day, ng/ml *	498.2	490.0	514.0	0.042	0 5 2 2
E ₂ on Cettolide start day, pg/mL ^a	(253.9-829.5)	(271.3–768.5)	(263.9–854.0)	0.942	0.552
Progesterone on Cetrotide start day, ng/mL*	0.4 (0.2–0.6)	0.4(0.3–0.6)	0.4(0.2–0.7)	0.286	0.384
LH on trigger day, mIU/mL*	2.6(1.6–4.4)	2.7(1.6–4.6)	2.6(1.5–4.0)	0.845	0.401
E on trigger day ng/ml*	2566.0(1622.	2883.0(1922.	2503.0(1642.	0.001	0.269
	0–3735.0)	5–4067.7)	0–3957.0)	0.001	
Progesterone on trigger day, ng/mL [#]	0.8(0.4)	0.9(0.4)	0.9(0.4)	<0.001	<0.001
Total dosage of Cetrotide, mg*	1.3(1.0–1.5)	0.8(0.5–0.9)	1.3(1.0–1.5)	<0.001	0.199
Premature LH rise ^{&c}	47 (9.0) ^b	94 (19.5)ª	42 (8.3) ^b	<0.001	0.695
Cycles for adjusting the Cetrotide dosage $^{\&d}$	NA	102(21.1)	NA	NA	NA
Number of oocytes retrieved [#]	10.7(4.2)	10.7(4.3)	10.2(4.4)	0.808	0.115
IV/E fertilization rate ^{&}	3574/4471	3114/3830	3319/4108	0 116	0 310
	(79.9)	(81.3)	(80.8)	0.110	0.515
ICSI fortilization rate ^{&}	844/1021	1025/1226	808/957	0 553	0 200
	(82.7)	(83.6)	(84.4)	0.555	0.250
Pata of available ombruos at cloavage [®]	2757/4306	2527/4038	2564/4026	0 171	0 746
Rate of available emblyos at cleavage	(64.0)	(62.6)	(63.7)	0.171	0.740
Ton quality embryo rate at cleavage ⁸	426/4306	367/4038	388/4026	0.210	0 604
Top quality embryo fate at cleavage	(9.9)	(9.1)	(9.6)	0.210	0.094
Endometrial thickness on trigger day, mm [#]	11.0(1.7)	10.9(1.7)	11.0(1.7)	0.086	0.507
Stage of transferred embryos				0.368	0.023
Blastocysts ^{&}	82/523 (15.7)	66/483 (13.7)	55/506 (10.9)		
Cleavage-stage embryos ^{&}	441/523	417/483	451/506		
cicavage stage ciribi yos	(84.3)	(86.3)	(89.1)		
Number of transferred embryos [#]	1.7(0.5)	1.7(0.5)	1.7(0.5)	0.955	0.729
One embryo transferred ^{&}	154/523	143/483	154/506	0 955	0 720
One embryo transienteu	(29.4)	(29.6)	(30.4)	0.955	0.725
Two embryos transferred ^{&}	369/523	340/483	352/506		
i wo embryos transieneu	(70.6)	(70.4)	(69.6)		
Score of transferred cleavage-stage	7 5(1 0)	7 /(1 1)	7 5(1 0)	0 121	0 / 10
embrvos#	7.5(1.0)	/.4(1.1)	,	0.121	0.410

312 *median(IQR), #mean(SD), & No.(%);

313 ^{ab} Comparisons between two groups; columns with the same superscript letter showed no statistically significant

314 difference, and vice versa;

315 ^c Premature LH rise refers to LH \ge 10 mIU/mL during COS;

316 ^d During the COS process, 21.2% of ITT patients in Group B (145 cycles) converted to a daily dosage of 0.25 mg

317 GnRH antagonist, including 95 cycles with a LH rise ≥10 mIU/mL, and 50 cycles with a LH rise >2× baseline LH (3

318 mIU/mL). 21.1% of PP patients (102 cycles) converted to a daily dosage of 0.25 mg GnRH, including 64 cycles with

319 a LH rise \geq 10 mIU/mL, and 38 cycles with a LH rise $>2\times$ baseline LH (3 mIU/mL);

320 P < 0.05 indicates a statistically significant difference.

321 Fresh ET ratio

Among all enrolled patients, 540 (26.3%) did not undergo fresh ET [Group A: 161 322 323 (23.5%); Group B: 201 (29.4%); Group C: 178 (26.0%)]. Excluding personal reasons, Group A had a significantly lower ET cancellation rate (128, 18.7%) compared to 324 325 Group B (165, 24.1%), with no differences compared to Group C (136, 19.9%). The primary reasons for cancellation in Group B were high progesterone levels on the 326 327 trigger day (75, 11.1%) and the risk of ovarian hyperstimulation syndrome (OHSS) [including $E_2 > 7,000 \text{ pg/mL}$ on the trigger day or retrieval of more than 20 oocytes 328 329 (63, 9.2%)] (Fig 1; S5 Table). No statistically significant differences were found in 330 embryo grading, progesterone and estrogen levels, or endometrial thickness on the day of endometrial transformation among the PP population across the three groups. 331

332 **Primary outcome**

333 The CPR in Group A (63.1%, 330/523) was significantly higher than in Group B (54.7%, 264/483; RD 8.4%, 95% CI 2.4%–14.5%; P = 0.007) and Group C (46.4%, 235/506; RD 334 16.7%, 95% CI 10.7%–22.7%; P < 0.001) (Table 3). Post-hoc analysis showed general 335 336 consistency of CPR results across different subgroups in Group A vs Group B and 337 Group A vs Group C (S1 Fig). The results of exploratory subgroup analysis for Group A 338 vs Group B showed that there were significant advantages in CPR observed in Group 339 A for the following subgroups: age \geq 30 years old, BMI between 18.5 to 23.9, infertility duration between 3 to 5 years, primary infertility, infertility for tubal and 340 341 mixed factors, AMH \leq 4.7ng/mL and basic FSH <10IU/L, and AFC \leq 20. Subgroup Analysis for Group A vs Group C showed significant improvements in CPR across 342

almost all the subgroups, including all age groups, both primary and secondary infertility, various AMH values, different AFC numbers in Group A. Only a few subgroups showed no difference: BMI <18.5 and >28, infertility duration > 5 years, infertility due to male factors, and bFSH \geq 10IU/L.

Table 3. Pregnancy outcomes of Group A compared with the other two

348 groups.

	No. (%)			Group A vs Group B			Group A vs Group C			
Outcomes	Group A	Group B	Group C	RD (%, 95%Cl)	RR(95%CI)	Ρ	RD (%, 95%Cl)	RR (95%CI)	Ρ	
Primary										
600	330/52	264/483	235/506	8.4 (2.4 to	1.154 (1.040	(1.040	16.7 (10.7	1.359 (1.212	-0.001	
CPR	3 (63.1)	(54.7)	(46.4)	14.5)	to 1.281)	.007	to 22.7)	to 1.523)	<0.001	
Secondary										
Biochemical	359/52	293/483	267/506	8.0 (2.1 to	1.132 (1.032	008	15.9 (10.0	1.301 (1.176	<0.001	
pregnancy rate	3 (68.6)	(60.7)	(52.8)	13.9)	to 1.241)	.008	to 21.8)	to 1.439)	<0.001	
Implantation rate	431/89	329/823	303/858	8.3 (3.7 to	1.209 (1.085	001	13.0 (8.4 to	1.368 (1.222	<0.001	
implantation rate	2 (48.3)	(40.0)	(35.3)	13.0)	to 1.346)	.001	17.6)	to 1.532)	0.001	
Live hirth rate	281/52	221/483	194/506	8.0 (1.8 to	1.174 (1.036	012	15.4 (9.4 to	1.401 (1.223	<0.001	
	3 (53.7)	(45.8)	(38.3)	14.1)	to 1.331)	.012	21.4)	to 1.606)	(0.001	
Early miscarriage	30/330	24/264	25/235	0 (-4.7 to	1.000 (0.599	> 99	-1.5 (-6.6 to	0.855 (0.516	0 541	
rate	(9.1)	(9.1)	(10.6)	4.6)	to 1.668)	2.55	3.5)	to 1.414)	0.341	
Late miscarriage	14/330	12/264	13/235	-0.3 (-3.6	0.933 (0.439	858	-1.3 (-4.9 to	0.767 (0.367	0.470	
rate	(4.2)	(4.5)	(5.5)	to3.0)	to 1.984)	.050	2.4)	to 1.601)	0.475	
Premature birth	53/330	37/264	38/235	2.0 (-3.7	1.146 (0.778	100	-0.1 (-6.3 to	0.993 (0.678	0 972	
rate	(16.1)	(14.0)	(16.2)	to7.8)	to 1.688)	.490	6.0)	to 1.455)	0.972	
Other birth										
outcomes										
Gestational	38.1	38.3	38.2(1.7	ΝΔ	NA	3/15	NA	NA	0 000	
weeks#	(2.4)	(2.4))	NA .	NA	.545	NA	NA .	0.909	
Birthweight										
Singleton, kg [#]	3.3(0.6)	3.3(0.6)	3.3(0.5)	NA	NA	.963	NA	NA	0.320	
Twin,kg [#]	2.5(0.5)	2.6(0.4)	2.5(0.4)	NA	NA	.394	NA	NA	0.727	

349 #mean (SD).

350 Secondary outcomes

351 Implantation rate, biochemical pregnancy rate, and LBR were significantly higher in

352 Group A (48.3%, 68.6%, and 53.7%, respectively) compared to Group B (40.0%, 60.7%,

and 45.8%, respectively) and Group C (35.3%, 52.8%, and 38.3%, respectively) (Table 3). No differences were observed among the groups regarding the mean number of retrieved oocytes, cycle cancellation rate (due to premature ovulation), main embryological outcomes (Table 2), early or late miscarriage, and premature birth (Table 3).

358 Adverse events

There were no significant differences among the three groups in terms of adverse events, including moderate or severe OHSS, ectopic pregnancy, gestational diabetes, stillbirth, placenta previa, premature rupture of membrane, pre-eclampsia, and neonatal complications such as small or large for gestational age, congenital anomalies, and neonatal death (Table 4).

Table 4. Adverse events of all randomized patients.

	Group A	Group B	Group C	Р
Maternal complications				
Moderate or severe OHSS	1/684 (0.1)	3/684 (0.4)	1/684 (0.1)	0.475
Ectopic pregnancy*	8/359 (2.2)	7/293 (2.4)	3/267 (1.2)	0.500
Gestational diabetes	18/330 (5.5)	21/264 (8.0)	11/235 (4.7)	0.263
Stillbirth	1/330 (0.3)	1/264 (0.4)	0/235 (0)	0.507
Placenta previa	0/330 (0)	3/264 (1.1)	1/235 (0.4)	0.086
Premature rupture of membrane	5/330 (1.5)	7/264 (2.7)	2/235 (0.9)	0.282
Pre-eclampsia	0/330 (0)	1/264 (0.4)	1/235 (0.4)	0.361
Neonatal complications				
Small for gestational age (<2.5 kg)	70/351 (19.9)	45/261 (17.2)	43/240 (17.9)	0.667
Large for gestational age (≥4.0 kg)	20/351 (5.7)	12/261 (4.6)	10/240 (4.2)	0.670
Congenital anomalies	1/351 (0.3)	1/261 (0.4)	0/240 (0)	0.504
Neonatal death	1/351 (0.3)	1/261 (0.4)	0/240 (0)	0.504

365 *In Group A, three patients had heterotopic pregnancy.

366 **Discussion**

367 In this multicenter randomized controlled clinical trial, we focused on the impact of

prednisone on the pregnancy outcomes of fresh ET cycles in the context of the GnRH-ant protocol. Our results demonstrate that the addition of low dose prednisone significantly enhances pregnancy outcomes without elevating adverse effects.

Prednisone is one of the most commonly used glucocorticoids for immune-regulatory 372 373 that widely used during IVF-ET. However, its use remains controversial. Previous 374 studies have confirmed that glucocorticoids were effective in improving clinical pregnancy rates in IVF-ET, especially for the patients with endometritis [28], positive 375 376 immune antibody [29], and repeated implantation failure [30]. However, it was also reported that prednisone could not improve the pregnancy outcomes of patients 377 with negative antibodies, endometriosis, or undergoing IVF-ET for the first time [31], 378 379 and thus against regular use of prednisone for non-selected IVF population [32]. Yun 380 sun et al. included 795 patients, who have undergone failures of 2 or more embryo transfer cycles, to receive prednisone or placebo randomly when they experienced 381 382 another time of frozen-thawed embryo transfer, and they found prednisone did not 383 improve LBR when compared to placebo, which raising questions about the value of prednisone in IVF-ET [33]. 384

However, it is important to note that these studies mainly focused on frozen embryo transfer cycles, and did not limited the protocols of COS. In this study, we only included patients who receiving fresh embryo transfer and undergoing GnRH-ant protocol for COS, and patients with immune abnormality and recurrent spontaneous abortion (RSA) were excluded. Our previous studies confirmed that GnRH-ant had

adverse effects on endometrial receptivity [34]. Thus, we chose CPR but not LBR as
the primary outcome for that the difference of CPR has the sufficient power to signal
the differences of endometrial receptivity since there was no difference about
embryos [35].

In our study, the patients in Group A achieved a significantly higher CPR and all other 394 395 pregnancy rates than the patients in Group C. Previous studies suggested that the 396 mechanisms of glucocorticoids enhancing pregnancy outcomes of IVF-ET cycles mainly lies in the following aspects. Firstly, glucocorticoids can inhibit immune 397 398 processes, decrease anti-phospholipid antibody and number of uNK cells [31]. The 399 immune inhibition effects of prednisone might contribute to the high CPR of Group A by mitigating immune damage to the endometrium caused by GnRH-ant [18, 19]. 400 401 Secondly, it can potentially promote the ovarian reaction to gonadotropin and modulate the hormonal environment, for instance, reducing progesterone levels 402 during follicular phase [36]. In our study, most of the COS indexes, including the dose 403 404 and duration of gonadotropins, level of E₂ on the trigger day, thickness of 405 endometrium, number of oocyte retrieved, and the rate of available embryos, showed no differences between Group A and Group C among ITT and PP patients. 406 407 These results showed that prednisone did not alter ovarian response to 408 gonadotropins or GnRH antagonist, or influence the thickness of endometrium and quality of embryos. However, the blood level of progesterone on the trigger day was 409 410 lower in Group A than in Group C. Alongside suppressing pituitary LH and ovarian progesterone production caused by full-dose GnRH-ant, the combined prednisone 411

412 might inhibit the adrenal production of progesterone [36], accounting overall for the 413 low level of progesterone on the trigger day observed in Group A. It has been 414 reported that elevated progesterone (even <1.5 ng/mL) on the trigger day adversely 415 affects the outcome of fresh ET, and patients with lower progesterone levels on the 416 trigger day exhibited a higher CPR and LBR [37-39].

In this study, we set another control group that using half-dose GnRH-ant and flexibly 417 418 elevating to the full dose until the trigger day once LH \geq 10 mIU/mL [40] or >2 419 baseline LH (>3 mIU/mL) [24]. This approach resulted in a significant reduction in the 420 total GnRH-ant dosage in Group B without any cycle cancellation due to premature 421 ovulation. However, the CPR and other pregnancy outcomes in Group B were inferior than those in Group A. Reducing the antagonist dosage may theoretically mitigate its 422 423 impact on the endometrium, but it is noteworthy that despite a substantial proportion (21.2%) of women undergoing the conversion of GnRH-ant dosage to full 424 dose, the premature LH rise rate in Group B was 21.3%, exceeding that of the other 425 426 two groups. Additionally, Group B exhibited the highest rate of fresh ET cancellation, 427 primarily attributed to elevated progesterone levels or the risk of OHSS (S5 Table). Levels of E_2 on the trigger day in Group B were significantly higher than those in the 428 429 other two groups, and the progesterone levels on the trigger day was significantly 430 higher in Group B than in Group A (Table 1). We hypothesize that low-dose GnRH-ant may attenuate the inhibition of endogenous FSH and LH, leading to increased E₂ and 431 432 progesterone production [41-43]. Our results demonstrated that it is better to use full-dose GnRH-ant combined with prednisone than use half-dose GnRH-ant for 433

alleviating adverse effects of GnRH-ant to endometrium and improving pregnancyrates.

Our post-hoc analysis showed a significant improved CPR in almost all the subgroups 436 437 of Group A when compared to Group C, including all the subgroups of ages, infertility types, AMH values, and AFC numbers (S1 Fig). However, there were no significant 438 439 differences between Group A and Group C in these subgroups that with a BMI less 440 than 18.5 or greater than 27.9, infertility duration exceeding 5 years, male factor infertility, and bFSH levels of 10 IU/L or higher. These results suggest that factors 441 442 other than GnRH antagonist-induced impairment of endometrial receptivity 443 influence pregnancy rates in these subgroups, such as obese, hyperlipidemia [44], 444 semen parameter [45], et al., which cannot be compensated by prednisone. When 445 compared to Group B, similar improvements of CPR in most subgroups of Group A were yielded, and only those subgroups with age younger than 30 years, BMI 446 between 24 and 27.9, infertility duration less than 3 years, and AMH levels higher 447 448 than 4.7 ng/ml did not exhibit differences. These results intimated that these 449 populations could possible be benefit from reducing the dosage of GnRH antagonist, consistent with our previous studies [23]. 450

451 Apart from the aforementioned results, there were no significant differences in 452 pregnancy loss (both early and late miscarriage rates), gestational age, birth weight, 453 or the incidence of maternal–fetal complications among the groups, indicating that 454 combination with low doses of prednisone during the GnRH-ant protocol was safe for

both the mothers and fetuses, which in consistent with previous studies. Additionally,
its affordability and convenience make it widely applicable in clinical practice [33].
Overall, the results of this study demonstrate that the combination of low-dose
prednisone with the GnRH-ant protocol definitively improves pregnancy outcomes of
fresh embryo transfer cycles, and surpassing the benefits of reducing the dosage of
GnRH antagonist alone.

461 **Limitations**

Several limitations of this study should be acknowledged. First, the administration of 462 prednisone 10 mg every morning was sustained from the initiation of rFSH to 11 days 463 after fresh ET, and alternative dose or duration might yield different outcomes. 464 465 Second, the absence of a half-dose GnRH-ant combined with prednisone group 466 precluded the evaluation of the combined effectiveness and safety of these two factors. Third, as an open-label study, a placebo control for prednisone was not 467 incorporated, potentially impacting result accuracy. Finally, the study population 468 469 consisted of young individuals with normal ovarian responses and was limited to Han 470 Chinese participants. Therefore, caution is advised in generalizing the conclusions drawn from our results to other cohorts of women. 471

472 **Conclusion**

The administration of low-dose prednisone emerges as a significant enhancer of pregnancy outcomes in fresh ET cycles for women undergoing the GnRH-ant protocol,

475 demonstrating notable improvements without incurring adverse consequences.

476 Funding

477	This trial was funded by the National Natural Science Foundation of China [82371704
478	(BFX), 82071712 (BFX), and 82271703(A-j Z)], Shanghai Municipal Education
479	commission-Gaofeng Clinical Medicine Grant Support (20181803, BFX), Health
480	Development Fund "Yiyuan Star Outstanding Young Physician" Project [SHWJRS
481	(2021)-99, BFX], the Beijing Health Promotion Association's "Reproductive Medicine
482	Young and Middle-aged Clinical Research" Project
483	(BJHPA-2022-SHZHYXZHQNYJ-LCH-009, BFX), and National Key R&D Program of China
484	(2022YFC2703800, A-j Z).

485 Acknowledgments

486 We thank all the staff involved in patients follow-up and information entry in the

487 three centers.

488

489 **References**

Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive
 technologies and global movements in the 21st century. Hum Reprod Update. 2015;21(4):411-426.

492 2. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist
493 versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
494 Hum Reprod Update. 2017;23(5):560-579.

495 3. Pal A, Mani T, Chinta P, Karthikeyan M, Kunjummen AT, Kamath MS. Effectiveness of GnRH
496 Agonist Short Protocol Versus GnRH Antagonist Protocol in POSEIDON Groups 3 and 4: a Retrospective
497 Cohort Study. Reprod Sci. 2023;30(8):2481-2488.

498 4. Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH
499 agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and
500 meta-analysis. Sci Rep. 2022;12(1):4456.

501 5. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in 502 ovarian stimulation for IVF. Hum Reprod Update. 2006;12(4):333-340.

503 6. Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE 504 guideline: ovarian stimulation for IVF/ICSI(dagger). Hum Reprod Open. 2020;2020(2):hoaa009.

505 7. Greco E, Donno V, Greco P, Arrivi C, Litwicka K, Varricchio MT. COVID-19 - compliant - IVF: 506 reorganized clinical practice taking into account the pandemic. Gynecol Endocrinol. 507 2022;38(6):474-477.

508 8. Expert Consensus Compilation Group of Reproductive Medicine Committee of China Medical 509 Women's Association. Expert consensus on standardized application of antagonist protocol in assisted

510 reproductive technology, Chin J Reprod Contracep 2022; 42, (2): 109-116.

511 9. D·I·R Annual 2022-The German **IVF-Registry** (2023). Available online at: 512 https://www.deutsches-ivf-register.de/ivf-international.php.

- 513 10. Lv M, Yu J, Chen P, Xiao Q, Lou L, Luo Y, et al. Ovarian stimulation in IVF couples with severe male 514 factor infertility: GnRH antagonist versus long GnRH agonist. Front Endocrinol (Lausanne). 515 2022;13:1037220.
- 516 11. Zhao D, Xie R, Li X. Comparison of pregnancy outcome after fresh embryo transfer between 517 GnRH antagonist and GnRH agonist regimens in patients with thin endometrium. Front Med 518 (Lausanne). 2023;10:1071014.
- 519 12. Wang X, Li W, Chen X, Zhang W, Chu M, Yin S, et al. Is the long-acting gonadotropin-releasing 520 hormone agonist long protocol better for patients with endometriosis undergoing IVF? Int J Gynaecol 521 Obstet. 2023;162(1):325-332.
- 522 13. Orvieto R, Meltzer S, Rabinson J, Zohav E, Anteby EY, Nahum R. GnRH agonist versus GnRH 523 antagonist in ovarian stimulation: the role of endometrial receptivity. Fertil Steril. 524 2008;90(4):1294-1296.
- 525 14. Bahceci M, Ulug U, Erden HF, Tosun S, Ciray N. Frozen-thawed cleavage-stage embryo transfer 526 cycles after previous GnRH agonist or antagonist stimulation. Reprod Biomed Online. 527 2009;18(1):67-72.
- 528 15. Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, et al. Transfer of Fresh versus Frozen Embryos in 529 Ovulatory Women. N Engl J Med. 2018;378(2):126-136.
- 530 16. Wei D, Liu JY, Sun Y, Shi Y, Zhang B, Liu JQ, et al. Frozen versus fresh single blastocyst transfer in 531 ovulatory women: a multicentre, randomised controlled trial. Lancet. 2019;393(10178):1310-1318.
- 532 17. Chen M, Li ZL, Lin H, Xia RB, Wang YL. Comparison of Pregnancy and Neonatal Outcomes 533 Between Fresh Embryo Transfer and Frozen-Thawed Embryo Transfer. Ther Hypothermia Temp Manag. 534 2023;13(3):120-125.
- 535 18. Xu B, Zhou M, Wang J, Zhang D, Guo F, Si C, et al. Increased AIF-1-mediated TNF-alpha expression 536 during implantation phase in IVF cycles with GnRH antagonist protocol. Hum Reprod. 537 2018;33(7):1270-1280.
- 538 19. Xu B, Wang J, Xia L, Zhang D, Wu X, Zhang A. Increased Uterine NK cell numbers and perforin 539 expression during the implantation phase in IVF Cycles with GnRH Antagonist Protocol. Sci Rep. 540 2017;7:39912.
- 541 20. Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, 542 Practice Committee of the American Society for Reproductive M. The role of immunotherapy in in
- 543 vitro fertilization: a guideline. Fertil Steril. 2018;110(3):387-400.
- 544 21. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good 545 model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y 546 Acad Sci. 2004;1024:124-137.
- 547 22. Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: unexpected targets and 548 mechanisms. Mol Endocrinol. 2011;25(7):1075-1086.
- 549 23. Zhang D, Xia L, Xu H, Chen Q, Jin B, Zhang A, et al. Flexible Low-Dose GnRH Antagonist Protocol Is
- 550 Effective in Patients With Sufficient Ovarian Reserve in IVF. Front Endocrinol (Lausanne). 2018;9:767.

551 24. Kao TC, Hsieh YC, Yang IJ, Wu MY, Chen MJ, Yang JH, et al. Progestin-primed ovarian stimulation 552 versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of 553 oocyte retrieval. J Formos Med Assoc. 2023;122(1):29-35.

554 25. Feng L, Fan R, Jiang A, Jiang J, Wang Q, Sun Y, et al. The effect of flexible low-dose GnRH 555 antagonist on pregnancy outcome in the fresh embryo transfer cycle of IVF-ET: a randomized 556 controlled trial. Reprod Biol Endocrinol. 2022;20(1):55.

557 26. Xu H, Zhao S, Gao X, Wu X, Xia L, Zhang D, et al. GnRH Antagonist Protocol With Cessation of 558 Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian 559 Reserve. Front Endocrinol (Lausanne). 2021;12:758896.

560 27. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation 561 and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73(6):1155-1158.

562 28. Alpha Scientists in Reproductive M, Embryology ESIGo. The Istanbul consensus workshop on 563 embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270-1283.

564 29. Zhang Y, Xu H, Liu Y, Zheng S, Zhao W, Wu D, et al. Confirmation of chronic endometritis in 565 repeated implantation failure and success outcome in IVF-ET after intrauterine delivery of the 566 combined administration of antibiotic and dexamethasone. Am J Reprod Immunol. 567 2019;82(5):e13177.

568 30. Fan J, Zhong Y, Chen C. Combined treatment of prednisone and aspirin, starting before ovulation 569 induction, may improve reproductive outcomes in ANA-positive patients. Am J Reprod Immunol. 570 2016;76(5):391-395.

571 31. Huang Q, Wu H, Li M, Yang Y, Fu X. Prednisone improves pregnancy outcome in repeated 572 implantation failure by enhance regulatory T cells bias. J Reprod Immunol. 2021;143:103245.

573 32. Lv Y, Chen Y, Hu L, Ding H, Liu M, Li H, et al. Is glucocorticoid use associated with a higher clinical 574 pregnancy rate of in vitro fertilization and embryo transfer? A meta-analysis. Heliyon. 575 2023;9(5):e15833.

576 33. Boomsma CM, Kamath MS, Keay SD, Macklon NS. Peri-implantation glucocorticoid administration 577 for assisted reproductive technology cycles. Cochrane Database Syst Rev. 2022;6(6):CD005996.

578 34. Sun Y, Cui L, Lu Y, Tan J, Dong X, Ni T, et al. Prednisone vs Placebo and Live Birth in Patients With 579 Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial. JAMA. 580 2023;329(17):1460-1468.

581 35. Chen Q, Fan Y, Zhou X, Yan Z, Kuang Y, Zhang A, et al. GnRH antagonist alters the migration of 582 endometrial epithelial cells by reducing CKB. Reproduction. 2020;159(6):733-743.

583 36. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired 584 endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized 585 trial comparing fresh and frozen-thawed embryo transfers in high responders. Fertil Steril. 586 2011;96(2):516-518.

587 37. Liu S, Shi L, Wang T, Shi J. Effect of low-dose dexamethasone on patients with elevated early 588 follicular phase progesterone level and pregnancy outcomes in IVF-ET treatment: A randomized 589 controlled clinical trial. Clin Endocrinol (Oxf). 2018;89(6):771-778.

590 38. Huang Y, Wang EY, Du QY, Xiong YJ, Guo XY, Yu YP, et al. Progesterone elevation on the day of 591 human chorionic gonadotropin administration adversely affects the outcome of IVF with transferred 592 embryos at different developmental stages. Reprod Biol Endocrinol. 2015;13:82.

593 39. Simon C, Cano F, Valbuena D, Remohi J, Pellicer A. Clinical evidence for a detrimental effect on 594 uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. 595 Hum Reprod. 1995;10(9):2432-2437.

596 40. Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, et al. Mild ovarian 597 stimulation for IVF. Hum Reprod Update. 2009;15(1):13-29.

598 41. Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing 599 hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist 600 during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol. 601 2008;47(1):66-74.

602 42. Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is 603 the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in 604 breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 605 2014;102(1):99-102.

606 43. Kummer NE, Weitzman VN, Benadiva CA, Schmidt DW, Engmann LL, Nulsen JC. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a 607 608 gonadotropin-releasing hormone antagonist cycle. Fertil Steril. 2011;95(8):2592-2594.

609 44. Yang F, Lu JC, Shen T, Jin YH, Liang YJ. Effect of hyperlipidemia on the outcome of in vitro 610 fertilization in non-obese patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 611 2023;14:1281794.

612 45. Ribas-Maynou J, Yeste M, Becerra-Tomas N, Aston KI, James ER, Salas-Huetos A. Clinical

613 implications of sperm DNA damage in IVF and ICSI: updated systematic review and meta-analysis. Biol

614 Rev Camb Philos Soc. 2021;96(4):1284-1300

Supplemental Content

- S1 Table. The criteria for cleavage embryos.
- S2 Table. The grading criteria for blastocysts.
- S3 Table. Definition of secondary outcomes.
- S4 Table. Definition of adverse events.
- S5 Table. Reasons for cancellation of embryo transfer.
- S1 Fig. Post-hoc analysis for Group A vs Group C and Group A vs Group B.

This supplemental material has been provided by the authors to provide readers with additional information about their research.

S1 Table. The criteria for cleavage embryos.

Score	0	1	2	3	4
Cell number (C)	<2	2-3	4-5	>10 & 6-7	8-10
Fragmentation (F)(%)	>50	26-50	11-25	5-10	<5
Symmetry (S)	Severely asymmetric	Symmetrical and uniform	-	-	-

The embryo scoring was performed on the morning of day 3. The embryo score is the sum of the scores for the

number of cells (C), degree of fragmentation (F), and symmetry (S). Embryos with a score \geq 9 were considered to

be of top quality, while those with a score <5 were classified as not suitable for transfer.

S2 Table. Blastocyst grading criteria.

Stage	Description				
1	Represents an early blastocyst with a small cavity, where the cavity				
1	volume is less than half of the total embryo volume.				
2	Indicates a blastocyst with a cavity volume equal to or greater than half				
2	of the total embryo volume.				
2	Represents an expanded blastocyst with the cavity completely occupying				
.	the total embryo volume.				
Δ	Represents a blastocyst with the cavity completely filled, resulting in an				
4	increase in total embryo volume and thinning of the zona pellucida.				
F	Represents a hatching blastocyst, where part of the blastocyst has				
5	emerged from the zona pellucida.				
<u> </u>	Represents a hatched blastocyst, where the entire blastocyst has				
0	emerged from the zona pellucida.				
Internal cell mass	Description				
	Numerous cells tightly packed together with uniform shape,				
A	diameter >60 μ m, uniform cell size, and compact fusion.				
	Represents fewer cells loosely arranged with irregular shape,				
В	diameter >60 $\mu m,$ uneven cell size, and a considerable portion lacking				
	fusion.				
<u> </u>	Represents very few cells, noticeably smaller than normal, with very few				
C	blastomeres.				
Trophectoderm	Description				
	Epithelial layer composed of numerous cells with a dense structure, >10				
٨	blastomeres distributed along the "equatorial plane" of the blastocyst,				
A	uniform in size, and all cells at the bottom surface of the blastocyst have				
	clear morphology with visible nuclei in most cells.				
	Represents an epithelial layer composed of fewer cells with a loose				
P	structure, around 10 blastomeres distributed along the "equatorial				
В	plane" of the blastocyst, uneven in size, and some cells at the bottom				
	surface having clear morphology with nuclei visible in some cells.				
	Represents an epithelial layer composed of sparse cells and a few large				
	cells, with >10 blastomeres distributed along the "equatorial plane" of				
С	the blastocyst, significantly uneven in size, significant fragments between				
	trophoblast cells and zona pellucida, and difficulty in identifying cells at				
	the bottom surface of the blastocyst.				

According to the Gardner scoring system, a comprehensive assessment of blastocyst quality includes evaluation of expansion status, inner cell mass development, and trophectoderm development. The available blastocysts refer to those in phases 3–6, with at least one of the internal cell mass or trophoblast cells graded as B or above.

Secondary Outcomes Definition The number of biochemical pregnancies (detection of **Biochemical** serum β -hCG \geq 5 mIU/mL measured 9–11 days after pregnancy rate embryo transfer) divided by the number of transplanted cases. Implantation rate Number of gestational sacs divided by the number of transplanted embryos. Early miscarriage rate Number of early miscarriage cases (occurring before 12 weeks of gestation) divided by the number of pregnant cases confirmed by ultrasound. Number of late miscarriage cases (occurring between 12 Late miscarriage rate and 28 weeks of gestation) divided by the number of pregnant cases confirmed by ultrasound. Number of premature births (delivery at >28 and <37 Premature birth rate weeks gestational age) divided by number of pregnant cases confirmed by ultrasound. Live birth rate Number of live births (deliveries of any number of newborns at \geq 28 weeks of gestation with signs of life) divided by the number of transplantation cycles. Fertilization rate Number of fertilized oocytes divided by oocytes (IVF) or MII oocytes (ICSI). Cleavage rate The number of fertilized oocytes that split into embryos divided by the number of all fertilized oocytes. Available embryo rate The number of available embryos divided by the number of all embryos. Top-quality embryo The number of top-quality embryos divided by the number of all embryos. rate Premature LH rise LH \geq 10 mIU/mL during COS. Number of cycles cancelled due to premature ovulation Rate of cycle cancellation due to divided by the total number of stimulation cycles. premature ovulation

S3 Table. Definition of secondary outcomes.

S4 Table. Definition of adverse events.

Adverse events	Definition			
Moderate or severe	OHSS was defined according to the Golan criteria.			
ovarian	Moderate OHSS was diagnosed when ultrasonographic			
hyperstimulation	ascites were present in addition to abdominal distension			
syndrome (OHSS)	and discomfort with or without nausea or vomiting. Severe			
	OHSS was diagnosed when there was clinical evidence of			
	ascites and/or hydrothorax or breathing difficulties with or			
	without hemoconcentration, coagulation abnormalities			
	and diminished renal function.			
Ectopic pregnancy	Ectopic pregnancy occurs when the embryo implants at any site other than the endometrial lining of the uterus.			
Gestational diabetes	GDM was defined as carbohydrate intolerance of variable			
mellitus (GDM)	severity with onset or first recognition during pregnancy as			
	determined from the diagnosis in the obstetrical medical			
	record.			
Stillbirth	The absence of signs of life at or after birth.			
Placenta previa	Placenta previa was used to describe a placenta that is			
	implanted over or very near the internal cervical opening.			
Premature rupture of	PROM was defined as rupture of the amniotic membranes			
membrane (PROM)	before the onset of labor including PROM of term and			
	preterm PROM.			
Pre-eclampsia	Pre-eclampsia was defined as the development of gestational hypertension with proteinuria (≥300 mg/24-h			
	urine collection or 30 mg/dL in a single urine sample) of			
	new onset after 20 weeks of gestation. Severe			
	pre-eclampsia was defined as symptoms of central			
	nervous system dysfunction, hepatic abnormality, severe			
	blood pressure elevation, thrombocytopenia, renal			
	abnormality or pulmonary edema.			
Congenital anomalies	Congenital anomalies were defined as structural or			
	functional anomalies that occur during intrauterine life,			
	including anomalies.			
Neonatal death	The death of a live-born neonate within 6 weeks after			
	delivery.			

S5 Table. Reasons for cancellation of embryo transfer.

	Group A	Group B	Group C	Р
	No. (%)	No. (%)	No. (%)	
The embryo transfer cancellation	128/684	165/684	136/684	0.035
rate	(18.7) ^b	(24.1) ^a	(19.9) ^{a,b}	
Reasons*				
(1) progesterone >1.7 ng/mL	59/684 (8.6)	75/684 (11.1)	54/684 (7.9)	0.121
once or >1.5 ng/mL twice				
(2) E ₂ >7,000 pg/mL, or	41/684 (6.0)	63/684 (9.2)	50/684 (7.3)	0.076
number of retrieved oocytes >20				
(3) Endometrial thickness on	40/684 (5.8)	58/684 (8.5)	47/684 (6.9)	0.160
HCG day <8 mm, or >14mm, or				
with a C type ultrasonic				
morphology				
(4) No available embryo	13/684 (1.9)	15/684 (2.2)	12/684 (1.8)	0.837
(5) Total days of GN <8	7/684 (1.0)	11/684 (1.6)	14/684 (2.0)	0.309
or >14				
Drop-out rate				
Quit	33/684 (4.8)	36/684 (5.3)	42/684 (6.1)	0.549

P < 0.05 indicates a statistically significant difference.

*Multiple reasons for some patients.

^{ab} Comparisons between two groups; columns with the same superscript letter showed no statistically significant difference, and vice versa.

S1 Fig. Post-hoc analysis for Group A vs Group B and Group A vs Group C.

	Group A(n/N, %)	Group B(n/N, %)	RD (95%CI)	
Overall	330/523(63.10)	264/483(54.66)	8.44(2.37 to 14.51)	
Age c 30	109/177(61 58)	95/160(59 38)	2 21(-8 25 to 12 66)	
≥30	221/346(63.87)	169/323(52.32)	11.55(4.12 to 18.99)	
BMI				
< 18.5	16/25(64.00)	18/29(62.07)	1.93(-23.87 to 27.74)	_
18.5-23.9	186/289(64.36)	148/280(52.86)	11.50(3.46 to 19.54)	
24-27.9	91/154(59.09)	64/125(51.20)	7.89(-3.82 to 19.60)	
≥ 28	37/55(67.27)	34/49(69.39)	-2.12(-20.01 to 15.78)	
Infertility duration				
<3	168/272(61.76)	141/242(58.26)	3.50(-4.98 to 11.98)	
3-5	134/201(66.67)	93/177(52.54)	14.12(4.30 to 23.95)	
> 5	28/50(56.00)	30/64(46.88)	9.13(-9.28 to 27.53)	
Type of infertility				
Primary	156/244(63.93)	133/245(54.29)	9.65(0.98 to 18.32)	
Secondary	174/279(62.37)	131/238(55.04)	7.32(-1.18 to 15.82)	
Causes of infertility				
Male factor	25/43(58.14)	26/45(57.78)	0.36(-20.27 to 20.99)	
Tubal factor	239/375(63.73)	193/343(56.27)	7.47(0.31 to 14.62)	
Mixed factors	66/105(62.86)	45/95(47.37)	15.49(1.84 to 29.14)	
AMH	252/402/62 70	170/227/62 02)	0.06(2.04 17.00)	
54.7	253/403(62.78)	70(128(57.25)	9.96(2.84 to 17.08)	
KECH	75/110(04.00)	79/130(37.23)	7.41(~4.36 (0 19.40)	-
< 10	303/481(62.99)	237/433(54 73)	8 26(1 89 to 14 63)	_
>10	27/42(64 29)	26/48(54.17)	10 12(-10 10 to 30 33)	
AFC	2712(01:25)	2010(01.11)	10.12(10.10 (0.00.00))	
≤ 20	256/416(61.54)	213/392(54.34)	7.20(0.41 to 14.00)	
> 20	74/107(69.16)	51/91(56.04)	13.11(-0.32 to 26.55)	
				-30 -20 -10 0 10 20 30 40 50
	Group A(n/N, %)	Group C(n/N, %)	RD	
	Group A(n/N, %)	Group C(n/N, %)	RD (95%CI)	1
Overall	Group A(n/N, %) 330/523(63.10)	Group C(n/N, %) 235/506(46.44)	RD (95%CI) 16.65(10.66 to 22.65)	
Overall Age	Group A(n/N, %) 330/523(63.10)	Group C(n/N, %) 235/506(46.44)	RD (95%CI) 16.65(10.66 to 22.65)	-
Overall Age < 30	Group A(n/N, %) 330/523(63.10) 109/177(61.58)	Group C(n/N, %) 235/506(46.44) 60/124(48.39)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54)	
Overall Age < 30 ≥ 30	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17)	
Overall Age < 30 ≥ 30 BMI	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17)	
Overall Age < 30 ≥ 30 BMI < 18.5	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11)	
Overall Age ≤ 30 ≥ 30 BMI < 18.5 18.5-23.9	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60)	RD (95%Cl) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73)	
Overall Age ≼ 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75)	RD (95%C1) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.523.9 24-27.9 ≥ 28	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 188/289(64.36) 91/154(59.09) 37/55(67.27)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3.5	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 169/272(61.76) 134/201(66.67) 29/6/67.67)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 122/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 20455(11.272)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(6.18 to 27.96)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Buttomark	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244/63.03)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/26//47.31)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Sacrondary	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/299(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/270(63.37)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246/45.53)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(6.41 to 25.27)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.523.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 188/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/260(47.31) 112/246(45.53)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(6.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.523.9 24.27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/299(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24(43(55.81))	RD (95%C)) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubol factor	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 166/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10)	RD (95%C)) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factors	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83)	RD (95%C)) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.63(8.01 to 25.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Mixed factors AMH	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(58.99) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83)	RD (95%C)) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 15.57(6.18 to 27.66) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.63(8.01 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Mixed factors AMH ≤ 4.7	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.63) 171/375(45.60)	RD (95%C1) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(0.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factor Mixed factors AMH ≤ 4.7	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21)	RD (95%C1) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 17.18(10.27 to 24.08) 15.45(3.12 to 27.77)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.523.9 24.27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Pauses of infertility Male factor Tubal factor Tubal factor Mixed factors AMH ≤ 4.7 > 4.7 > 4.7	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 188/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 122/260(47.31) 112/246(45.53) 24(43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21)	RD (95%C) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 17.18(10.27 to 24.08) 15.45(3.12 to 27.77)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5 24.27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infentility Primary Secondary Causes of infentility Male factor Tubal factor Tubal factor Tubal factor Mixed factors AMH ≤ 4.7 > 4.7 > 4.7 > 4.7	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/299(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25(43(58.14) 293/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24(43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21) 215/462(46.54)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.55(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 17.18(10.27 to 24.08) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.523.9 24.27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factor Mixed factors AMH ≤ 4.7 > 4.7 > 4.7 > 4.7 > 4.7 > 4.7	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99) 27/42(64.29)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21) 215/462(46.54) 19/43(44.19)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.35(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 7.18(10.27 to 24.08) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73) 20.10(-0.64 to 40.84)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.55 18.52 18.52 24.27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Primary Secondary Causes of infertility Male factor Tubal factor Mixed factors AMH ≤ 4.7 > 4.7 bFSH < 10 2 10 AFC	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99) 27/42(64.29)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21) 215/462(46.54) 19/43(44.19)	RD (95%C) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.55(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.63(8.07 to 25.18) 16.63(3.33 to 28.73) 16.03(3.33 to 28.73) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73) 20.10(-0.64 to 40.84)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factor Tubal factor Mixed factor Secondary Causes of infertility Male factor Tubal factor Mixed factor Mixed factor Secondary Causes of infertility ABF 4.7 > 4.7 > 4.7 > 5H < 10 210 AFC	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99) 27/42(64.29)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21) 215/462(46.54) 19/43(44.19) 183/410(44.63)	RD (95%C) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.55(7.69 to 25.01) 18.57(9.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.63(8.07 to 25.18) 16.63(8.14 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 17.18(10.27 to 24.08) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73) 20.10(-0.64 to 40.84) 16.90(10.20 to 23.61)	
Overall Age < 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3.5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factor Mixed factors AMH ≤ 4.7 > 5: SH < 10 ≥ 10 AFC ≤ 20 > 20	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99) 27/42(64.29) 256/416(61.54) 74/107(69.16)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30(67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.63) 171/375(45.60) 62/126(49.21) 215/462(46.54) 19/43(44.19) 183/410(44.63) 52/96(54.17)	RD (95%C) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.55(7.69 to 25.01) 15.57(6.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.63(8.07 to 25.25) 18.63(11.43 to 25.23) 16.03(3.33 to 28.73) 17.18(10.27 to 24.08) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73) 20.10(-0.64 to 40.84) 16.90(10.20 to 23.61) 14.99(1.73 to 28.26)	
Overall Age ≤ 30 ≥ 30 BMI < 18.5 18.5-23.9 24-27.9 ≥ 28 Infertility duration < 3 3-5 > 5 Type of infertility Primary Secondary Causes of infertility Male factor Tubal factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Tubal factor Secondary Causes of infertility Male factor Tubal factor Secondary Causes of infertility Male factor Secondary Causes of infertility Secondary Causes of infertility Secondary Secondary Causes of infertility Secondary S	Group A(n/N, %) 330/523(63.10) 109/177(61.58) 221/346(63.87) 16/25(64.00) 186/289(64.36) 91/154(59.09) 37/55(67.27) 168/272(61.76) 134/201(66.67) 28/50(56.00) 156/244(63.93) 174/279(62.37) 25/43(58.14) 239/375(63.73) 66/105(62.86) 253/403(62.78) 75/116(64.66) 303/481(62.99) 27/42(64.29) 256/416(61.54) 74/107(69.16)	Group C(n/N, %) 235/506(46.44) 60/124(48.39) 175/382(45.81) 12/27(44.44) 128/287(44.60) 70/153(45.75) 25/39(64.10) 104/229(45.41) 101/210(48.10) 30/67(44.78) 123/260(47.31) 112/246(45.53) 24/43(55.81) 152/337(45.10) 59/126(46.83) 171/375(45.60) 62/126(49.21) 215/462(46.54) 19/43(44.19) 183/410(44.63) 52/96(54.17)	RD (95%CI) 16.65(10.66 to 22.65) 13.19(1.85 to 24.54) 18.06(10.95 to 25.17) 19.56(-7.00 to 46.11) 19.76(11.79 to 27.73) 13.34(2.27 to 24.41) 3.17(-16.33 to 22.67) 16.55(7.69 to 25.01) 18.57(6.18 to 27.96) 11.22(-6.97 to 29.42) 16.63(8.07 to 25.18) 16.84(8.41 to 25.27) 2.33(-18.60 to 23.25) 18.63(11.43 to 25.83) 16.03(3.33 to 28.73) 15.45(3.12 to 27.77) 16.46(10.19 to 22.73) 2.0.10(-0.64 to 40.84) 16.90(10.20 to 23.61) 14.99(1.73 to 28.26)	

The upper panel exhibits the Post-hoc analysis of primary outcome for Group A vs Group B, and the lower panel exhibits the results for Group A vs Group C.

А	Group A(n/N, %)	Group B(n/N, %)	RD (95%CI)	
Overall	330/523(63.10)	264/483(54.66)	8.44(2.37 to 14.51)	
Age				
<30	109/177(61.58)	95/160(59.38)	2.21(-8.25 to 12.66)	
> 30	221/346(63.87)	169/323(52.32)	11.55(4.12 to 18.99)	
BMI	221040(00.07)	1001020(02102)	11.55(1.12 10 10.55)	
<18.5	16/25(64.00)	18/29(62.07)	1 93(-23 87 to 27 74)	
18 5.23 0	186/280(64.36)	148/280(52.86)	11 50(3 46 to 19 54)	
24.27.0	01/15/(50.00)	64/105/51.00)	7 90(2 92 to 10 60)	_
> 29	27/55(67.27)	24/40(60.20)	2 12(20 01 to 15 79)	
≥ 20	37/33(07.27)	34/49(09.39)	-2.12(-20.01 (0 13.78)	
Intertility duration	100/070/01 70	141/242/50.26)	2 50(4 00 ++ 11 00)	
<3	168/272(61.76)	141/242(58.26)	3.50(-4.98 to 11.98)	1
3-5	134/201(66.67)	93/177(52.54)	14.12(4.30 to 23.95)	
>5	28/50(56.00)	30/64(46.88)	9.13(-9.28 to 27.53)	
Type of infertility				
preprint doi: https://doi.org/10.1101/2 (which was not certified by peer r	2024.10.11.24315288; this version posted Oc eview) is the author/funder, who has granted	tober 13, 2024. The copyright ho medRxiv a license to display the	plder for this 0.98 to 18.32)	_
Secondary It is mad Causes of infertility	perpetuity.79(62.37) le available under a CC-BY 4.0 International li	131/238(55.04) cense	7.32(-1.18 to 15.82)	
Male factor	25/43(58.14)	26/45(57.78)	0.36(-20.27 to 20.99)	
Tubal factor	239/375(63.73)	193/343(56.27)	7.47(0.31 to 14.62)	
Mixed factors	66/105(62.86)	45/95(47.37)	15.49(1.84 to 29.14)	_
AMH				
≤ 4.7	253/403(62.78)	178/337(52.82)	9.96(2.84 to 17.08)	_
>4.7	75/116(64.66)	79/138(57.25)	7.41(-4.58 to 19.40)	
bESH				
<10	303/481(62.99)	237/433(54 73)	8 26(1 89 to 14 63)	
> 10	27/42(64 29)	26/48(54 17)	10 12(-10 10 to 30 33)	
AEC	2.7742.(04.2.37	20(40(34.17)	10.12(10.1010 30.33)	_
< 20	256/416(61.54)	212/202/54 24)	7 20(0 41 to 14 00)	_
>20	74/107(60.16)	213/392(34.34) 51/01(56.04)	12 11(-0 22 to 26 55)	
-20	/4/10/(05.10)	51/51(50.04)		
				-30 -20 -10 0 10 20 30 40 50
В	Group A(n/N, %)	Group C(n/N, %)	RD(95%CI)	
Overall	330/523(63.10)	235/506(46.44)	16.65(10.66 to 22.65)	
Age				
<30	109/177(61.58)	60/124(48.39)	13.19(1.85 to 24.54)	
≥30	221/346(63.87)	175/382(45.81)	18.06(10.95 to 25.17)	
BMI			,	
<18.5	16/25(64.00)	12/27(44.44)	19.56(-7.00 to 46.11)	
18 5-23 9	186/289(64-36)	128/287(44 60)	19.76(11.79 to 27.73)	
24-27.9	91/154(59.00)	70/153(45.75)	13 34(2 27 to 24 41)	
>38	27/55/67 27)	25/20/64 10)	3 17(-16 22 to 22 67)	
≥20 Infactility denotion	51/55(67.27)	25/59(04.10)	5.17(-10.55 to 22.07)	
intertility duration	1/0/000//1 0/1	10.0000000000000	10 00/0 /0 01 010	
<3	168/272(61.76)	104/229(45.41)	16.35(7.69 to 25.01)	
3-5	134/201(66.67)	101/210(48.10)	18.57(9.18 to 27.96)	_ _
>5	28/50(56.00)	30/67(44.78)	11.22(-6.97 to 29.42)	
Type of infertility				
Primary	156/244(63.93)	123/260(47.31)	16.63(8.07 to 25.18)	
Secondary	174/279(62.37)	112/246(45.53)	16.84(8.41 to 25.27)	
Causes of infertility				
Male factor	25/43(58.14)	24/43(55.81)	2.33(-18.60 to 23.25)	
Tubal factor	239/375(63,73)	152/337(45.10)	18.63(11.43 to 25.83)	
Mixed factors	66/105(62.86)	59/126(46.83)	16.03(3.33 to 28.73)	
AMU	00/10/(02.00)	57120(40.05)	10.05(0.05 (0 20.15)	
~4.7	052/402/20 705	171/275/45 (0)	17 19/10 27 1/ 24 00	_
24.7	255/403(62.78)	1/1/5/5(45.00)	17.18(10.27 to 24.08)	
54.7	15/116/64 66)		13 13 1 1 1 10 11 771	



S Fig 1

